Sarcopenia in Children with Solid Organ Tumors: An Instrumental Era

Area of Science:

• Pediatric Oncology
• Clinical Nutrition
• Biomarkers

Background:

• Sarcopenia is an emerging prognostic marker across diverse patient groups.
• Children with cancer, particularly those with solid organ tumors, are susceptible to skeletal muscle mass loss.
• Factors like metabolic changes, inflammation, and cancer therapy exacerbate muscle wasting in pediatric patients.

Purpose of the Study:

• To review the current understanding of sarcopenia in pediatric solid organ tumors.
• To detail the pathophysiological mechanisms driving sarcopenia in this population.
• To explore methods for measuring muscle mass, strength, and function, including AI-based techniques.

Main Methods:

• Review of current literature on sarcopenia in pediatric oncology.
• Analysis of pathophysiological mechanisms contributing to muscle loss.
• Evaluation of diagnostic techniques for muscle assessment, including AI applications.

Main Results:

• Sarcopenia is a relevant prognostic marker for adverse outcomes in children with solid organ tumors, especially in high-risk groups.
• It offers an objective method to quantify muscle wasting.
• The study emphasizes the need for objective tools to predict and improve outcomes.

Conclusions:

• Sarcopenia is a valuable tool for predicting outcomes in pediatric patients with solid organ tumors.
• Understanding sarcopenia's mechanisms and measurement is crucial for clinical application.
• Further research and application of AI-based techniques can enhance patient care and prognosis.